Technical analysis of Elicio Therapeutics, Inc. (ELTX): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases. The company's primary experimental drug, ELI-002, is an AMP therapeutic vaccine specifically formulated to target KRAS-driven cancers.
Price Performance
| 1 month | -43.09% |
| 3 months | -54.03% |
| Year-to-date | -77.76% |
| 1 year | -84.61% |
52-Week Range
| 52-week High | $16.00 |
| 52-week Low | $1.71 |
| Avg Volume (90d) | 1.3M |
Technical Indicators
| SMA 50 | $2.89 |
| SMA 200 | $7.79 |
| Beta | 1.88 |
| 30-day Volatility (annualised) | 47.8% |
| Price vs SMA 50 | -38.7% |
| Price vs SMA 200 | -77.3% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $9.29 | |
| 2025-11 | $9.36 | +0.8% |
| 2025-12 | $7.96 | -15.0% |
| 2026-01 | $7.60 | -4.5% |
| 2026-02 | $12.99 | +70.9% |
| 2026-03 | $10.69 | -17.7% |
| 2026-04 | $10.62 | -0.7% |
| 2026-05 | $11.44 | +7.7% |
| 2026-06 | $3.91 | -65.8% |
| 2026-07 | $2.80 | -28.4% |
| 2026-08 | $2.70 | -3.6% |
| 2026-09 | $1.77 | -34.4% |
Price
| Price | $1.77 |
| Market Cap | $34M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 3.91 |
| EV / EBITDA | -0.90 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 1.78 |
| Current Ratio | 2.77 |
| Piotroski F-Score | 4 |
| Altman Z-Score | -13.92 |